CD276 and breast cancer: In turn, Srivastava et al. (108) used a logic-gated CAR-T cell therapy in which ROR1 CAR was combined with a SynNocht receptor against a different tumor antigen (EpCAM or B7-H3) to treat animal models of human breast cancer.